Albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-20. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Food does not significantly influence the oral bioavailability of pregabalin. Conversely, food increases the area-under-curve levels of gabapentin by about 10%. Drugs that increase the transit time of gabapentin in the small intestine can increase its oral bioavailability; when gabapentin was co-administered with oral morphine (which slows intestinal peristalsis), the oral bioavailability of a 600 mg dose of gabapentin increased by 50%. The oral bioavailability of gabapentin enacarbil (as gabapentin) is greater than or equal to 68%, across all doses assessed (up to 2,800 mg), with a mean of approximately 75%. In contrast to the other gabapentinoids, the pharmacokinetics of phenibut have been little-studied, and its oral bioavailability is unknown. However, it would appear to be at least 63% at a single dose of 250 mg, based on the fact that this fraction of phenibut was recovered from the urine unchanged in healthy volunteers administered this dose. Gabapentin at a low dose of 100 mg has a Tmax (time to peak levels) of approximately 1.7 hours, while the Tmax increases to 3 to 4 hours at higher doses. The Tmax of pregabalin is generally less than or equal to 1 hour at doses of 300 mg or less. However, food has been found to substantially delay the absorption of pregabalin and to significantly reduce peak levels without affecting the bioavailability of the drug; Tmax values for pregabalin of 0.6 hours in a fasted state and 3.2 hours in a fed state (5-fold difference), and the Cmax is reduced by 25–31% in a fed versus fasted state.
In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of people twelve years of age and older with stage IIB or IIC melanoma following complete resection. In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of renal cell carcinoma for people at intermediate-high or high risk of recurrence following nephrectomy. Approval was based on KEYNOTE-564, a multicenter, randomized (1:1), double-blind, placebo-controlled trial in 994 participants with intermediate-high or high risk of recurrence of RCC, or M1 no evidence of disease. In March 2022, the US FDA approved pembrolizumab for the treatment of advanced endometrial cancer. In January 2023, the US FDA approved pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung cancer. In October 2023, the US FDA approved pembrolizumab to be used with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. In January 2024, the US FDA approved pembrolizumab, in combination with chemoradiotherapy for the treatment of people with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. In June 2024, the US FDA approved pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial carcinoma.
==== Academic licencing, licence steering and AI commercialisation ==== The use of academic research for Large Language Models (LLMs) has sparked debate within the Open Access movement. Academics accuse publishers of steering authors towards restrictive licences to retain exclusive commercial rights for AI training deals. In 2024, publishers like Taylor & Francis announced lucrative AI training partnerships, often without consulting authors. This dynamic complicates copyright litigation, as seen in the US when Elsevier sued Meta over Llama AI models, acting as the class representative due to exclusive commercial rights granted by authors.
=== Pharmacokinetics === The oral bioavailability of oxandrolone is 97%. Its plasma protein binding is 94 to 97%. The drug is metabolized primarily by the kidneys and to a lesser extent by the liver. Oxandrolone is the only AAS that is not primarily or extensively metabolized by the liver, and this is thought to be related to its diminished hepatotoxicity relative to other AASs. Its elimination half-life is reported as 9.4 to 10.4 hours, but is extended to 13.3 hours in the elderly. About 28% of an oral dose of oxandrolone is eliminated unchanged in the urine and 3% is excreted in the feces.
Considering all decay modes, various models indicate a shift of the center of the island (i.e., the longest-living nuclide) from 298Fl to a lower atomic number, and competition between alpha decay and spontaneous fission in these nuclides; these include 100-year half-lives for 291Cn and 293Cn, a 1000-year half-life for 296Cn, a 300-year half-life for 294Ds, and a 3500-year half-life for 293Ds, with 294Ds and 296Cn exactly at the N = 184 shell closure. It has also been posited that this region of enhanced stability for elements with 112 ≤ Z ≤ 118 may instead be a consequence of nuclear deformation, and that the true center of the island of stability for spherical superheavy nuclei lies around 306Ubb (Z = 122, N = 184). This model defines the island of stability as the region with the greatest resistance to fission rather than the longest total half-lives; the nuclide 306Ubb is still predicted to have a short half-life with respect to alpha decay. The island of stability for spherical nuclei may also be a "coral reef" (i.e., a broad region of increased stability without a clear "peak") around N = 184 and 114 ≤ Z ≤ 120, with half-lives rapidly decreasing at higher atomic number, due to combined effects from proton and neutron shell closures. Another potentially significant decay mode for the heaviest superheavy elements was proposed to be cluster decay by Romanian physicists Dorin N. Poenaru and Radu A. Gherghescu and German physicist Walter Greiner.
Sources: en.wikipedia.org
The Administrative and Program Enrichment Core coordinates Center activities, provides biostatistical support, promotes community engagement, and facilitates career development through seminars, workshops, and the internationally recognized Masoro-Barshop Conference on Aging. The Aging Animal and Functional Assessment Core offers access to aged animal colonies, longevity studies, and comprehensive assessments of physical and physiological function. The GeroMetabolism Core provides advanced metabolomic, lipidomic, and metabolic phenotyping capabilities that enable investigators to examine metabolic mechanisms underlying aging and age-related diseases. The Pathology Core delivers expert histopathologic evaluation and disease phenotyping across multiple organ systems, while the Pharmacology and Drug Design Core supports the identification, optimization, and evaluation of pharmacological interventions targeting aging pathways. Finally, the Research Development Core expands aging research by providing pilot funding, mentorship, trainee support, and access to Center resources for investigators both within UT Health San Antonio and across the United States. A distinguishing strength of the San Antonio Nathan Shock Center is its commitment to developing the next generation of geroscientists. Through pilot grant programs, mentorship initiatives, trainee internships, educational workshops, and collaborative research opportunities, the Center provides critical support for early-stage investigators pursuing careers in aging research.
First, it should dissolve the solid compound to be analysed (with or without the aid of a cosolvent or additive), thus allowing molecules of that compound to diffuse to the surface layers, replenishing the sample molecules that have been ionized or destroyed by interaction with the fast atom beam. Another mechanism for explanation of ion formation in FAB involves the idea that sputtering occurs from the bulk rather than the surface, but in that case, the solubility is still largely important to insure homogeneity of solid analyte in the bulk solution. Secondly, the matrix should have a low volatility under the conditions of the mass spectrometer. As mentioned above, as the matrix is depleted, the ionization decreases as well, so maintaining the matrix is vital. Thirdly, the matrix should not react with the solid analyte in question, or if it does react, it should be in an understood and reproducible way. This ensures reproducibility of analysis and identification of the actual analyte rather than a derivative of the analyte. The most commonly used compounds as a matrix are variations of glycerol, such as glycerol, deuteroglycerol, thioglycerol, and aminoglycerol. If the sample cannot dissolve in the chosen matrix, such as glycerol, a cosolvent or additive can be mixed with the matrix to facilitate the dissolving of the solid analyte. For example, chlorophyll A is completely insoluble in glycerol, but by mixing in a small amount of Triton X-100, a derivative of polyethylene glycol, the chlorophyll becomes highly soluble within the matrix.
==== Human ==== The human genome encodes 16 serpin clades, termed serpinA through serpinP, including 29 inhibitory and 7 non-inhibitory serpin proteins. The human serpin naming system is based upon a phylogenetic analysis of approximately 500 serpins from 2001, with proteins named serpinXY, where X is the clade of the protein and Y the number of the protein within that clade. The functions of human serpins have been determined by a combination of biochemical studies, human genetic disorders, and knockout mouse models.
Distinguished as a biochemist. Was the first to show the possibility of using counter-current liquid-liquid extraction in the separation of N-acetylamino acids. In collaboration with A.J.P. Martin this led to the development of partition chromatography, which they have applied with conspicuous success in problems related to the composition and structure of proteins, particularly wool keratin. Synge's recent work on the composition and structure of gramicidins is outstanding and illustrates vividly the great advances in technique for which he and Martin are responsible. In 1963 he was elected a Fellow of the Royal Society of Edinburgh. His proposers were Magnus Pyke, Andrew Phillipson, Sir David Cuthbertson and John Andrew Crichton. He was for several years the treasurer of the Chemical Information Group of the Royal Society of Chemistry, and was an honorary Professor in Biological Sciences at the University of East Anglia from 1968 to 1984. He was awarded an honorary Doctor of Science (ScD) from the University of East Anglia in 1977, and an honorary doctorate from the Faculty of Mathematics and Science at Uppsala University, Sweden in 1980.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.